U.S. Probes Theranos Complaints
wsj.com
wsj.com
From the article:
"hadn’t fully assembled the proprietary machines used for the herpes study when the experiments began" ... "company underreported the rate at which the machines broke down during the study" ... "employee also alleged that some crucial parts of the devices ... were modified to improve their accuracy"
FDA is generally skeptical of validation data not generated from "production equivalent" technology, but they get even more skeptical if you tell them something is X and it turns out to be Y down the road. That (rightly) sends them on a fishing expedition.
To elaborate point 1:
- If the crucial parts of the devices that "were modified to improve accuracy" were modified early on in the study the data could be representative of the final product.
- The same applies for the devices not being fully assembled. If they weren't fully assembled, and the data were still good enough to defend a 510k, then the data should represent worst case usage, unless full assembly would somehow make the technology less performant.
While the medical field certainly has additional concerns I do see a time where, with proper processes in place, that the final delivery may not exactly be what entered the certification phase.
I disagree. 21 CFR 820 is deliberately written such that it does not prescribe any one specific development process; AAMI TIR-45 for example aligns agile methodologies with medical device software development and is an FDA recognized consensus standard.
What regulatory bodies do demand is that one document what one will do, and then, actually do what one has documented. Sounds like Theranos had trouble with that.
This sounds really bad. When you have this huge amount of uncertainty in results, it calls into question their whole finger prick blood sampling methodology. I'm starting to think that it's impossible to get an accurate blood work from a finger prick only.
There are lots of industries you can disrupt, or fail fast at, but lab testing isn't one of them.
The options include partial thyroidectomy/ radioiodine therapy / carbimazole, propylthiouracil and a few other niche options for use use in special situations like pregnancy associated thyrotoxicosis.
It is possible, but just for certain test types and error rates. The basic problem is the blood drawn from a finger prick is affected by exactly where it goes in and how much skin tissue is picked up. This variability gets averaged out with a large venous draw and so is not quite as bad - there is still a large variability with even normal blood tests for certain test types.
The tests that work OK are things where you just want a yes/no answer (do you have HSV1) and very poorly for things where you are wanting to measuring exact levels of something.
None of this is new to the industry.
If the issue is skin contamination, measure the level of some substance that is correlated with that contamination, then apply a correction factor
If it is the latter, case marked variations could have a number of explanations, ranging from the inevitable inaccuracy of finger prick collection, through errors due to dilution by Theranos, problems with the technology and equipment and diurnal variation of TSH levels
See also Diurnal variation in TSH and free thyroid hormones in patients on thyroxine replacement. http://www.ncbi.nlm.nih.gov/pubmed/2588938
>To Read the Full Story, Subscribe or Sign In
Update: too bad Theranos isn't publicly traded, I'd love to be able and bet against them.
I don't give one sordid fuck about Holmes, let's talk about Theranos. How is this a successful business in ANY capacity? Has it made a DIME that didn't come from an investor? Does it have ANY reputation that doesn't involve a spunky CEO?
It has yet to be proven that Theranos did in fact falsify data, though.
This is EH's response to the WSJ article. Very positive defence of EH. Just wanted to add this for an alternative take.